SCHEMBL8226340

SCHEMBL8226340

Cn1c(=O)oc2ccc(CNC(=O)c3cc(C(=O)NCC(F)(F)F)n4nccc4n3)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 2/20 0.37
ADAMTS4 O75173 1/20 0.37
MMP3 P08254 1/20 0.37
MMP8 P22894 1/20 0.37
MMP12 P39900 1/20 0.37
METTL3 Q86U44 3/20 0.37
METTL14 Q9HCE5 2/20 0.37
LOXL2 Q9Y4K0 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
JAK2 O60674 1/20 0.35
LYN P07948 1/20 0.35
FLT3 P36888 1/20 0.35
SYK P43405 1/20 0.35
KMT2A Q03164 3/20 0.35
LMNA P02545 3/20 0.35
MEN1 O00255 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
THRB P10828 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10163587 0.94 MMP13 (0.37) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8225958 0.90 TP53 (0.44) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8227563 0.89 CDK2 (0.37) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8229564 0.89 CACNA1G (0.43) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8225360 0.89 LMNA (0.41) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162873 0.89 TP53 (0.44) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10162840 0.89 L3MBTL1 (0.48) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL10210496 0.89 MMP13 (0.43) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL13161853 0.89 GLS (0.40) MMP13ADAMTS4MMP3MMP8MMP12
SCHEMBL8225378 0.89 KCNN3 (0.43) KMT2ALMNAMEN1MAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
WO-2007139856-A2 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS, INC. (US) 2007-12-06 WO disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MMP13 1/4885ADAMTS4 38/4885MMP3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.